Most importantly, they demonstrated that targeted glutamine blockade interfered with tumour growth by acting on the tumour cells, an effect that required CD8+ T cell anti-tumour responses as shown by a loss of efficacy of JHU083 in Rag2–/– mice or upon depletion of CD8+ T cells in the tumour-recipient mice (Leone et al. 2019). The gene discussed is CD8A; the disease is neoplasm.